Sentry Investment Management LLC Has $37,000 Stock Position in Incyte Co. (NASDAQ:INCY)

Sentry Investment Management LLC cut its position in Incyte Co. (NASDAQ:INCY) by 39.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 562 shares of the biopharmaceutical company’s stock after selling 370 shares during the quarter. Sentry Investment Management LLC’s holdings in Incyte were worth $37,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of INCY. ProShare Advisors LLC increased its stake in shares of Incyte by 14.4% in the first quarter. ProShare Advisors LLC now owns 63,086 shares of the biopharmaceutical company’s stock worth $3,594,000 after purchasing an additional 7,925 shares during the period. Kennedy Capital Management LLC acquired a new position in shares of Incyte during the first quarter worth approximately $463,000. Magnetar Financial LLC bought a new stake in shares of Incyte in the first quarter valued at approximately $1,817,000. Andra AP fonden grew its stake in shares of Incyte by 35.2% in the second quarter. Andra AP fonden now owns 247,800 shares of the biopharmaceutical company’s stock worth $15,022,000 after acquiring an additional 64,500 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in Incyte by 19.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 152,452 shares of the biopharmaceutical company’s stock worth $8,652,000 after acquiring an additional 24,328 shares during the period. Institutional investors own 96.97% of the company’s stock.

Insider Activity

In related news, EVP Jonathan Elliott Dickinson sold 8,450 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $62.36, for a total transaction of $526,942.00. Following the completion of the sale, the executive vice president now directly owns 36,390 shares of the company’s stock, valued at $2,269,280.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, insider Thomas Tray sold 572 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $62.94, for a total value of $36,001.68. Following the sale, the insider now directly owns 24,825 shares in the company, valued at $1,562,485.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jonathan Elliott Dickinson sold 8,450 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $62.36, for a total transaction of $526,942.00. Following the completion of the sale, the executive vice president now owns 36,390 shares in the company, valued at approximately $2,269,280.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 17.60% of the company’s stock.

Incyte Trading Up 2.0 %

Shares of NASDAQ INCY opened at $77.28 on Wednesday. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $77.37. The company has a current ratio of 1.87, a quick ratio of 1.82 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $66.49 and a two-hundred day moving average of $62.30. The company has a market cap of $14.89 billion, a PE ratio of 552.04, a P/E/G ratio of 6.68 and a beta of 0.71.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.07 EPS for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.12). Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the previous year, the business posted $0.91 earnings per share. The firm’s quarterly revenue was up 23.8% on a year-over-year basis. As a group, equities analysts expect that Incyte Co. will post 0.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on INCY. Oppenheimer boosted their price objective on shares of Incyte from $81.00 to $82.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. JMP Securities reiterated a “market perform” rating on shares of Incyte in a research report on Tuesday, September 17th. The Goldman Sachs Group boosted their price objective on Incyte from $63.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Citigroup raised their target price on Incyte from $92.00 to $97.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, Wolfe Research initiated coverage on shares of Incyte in a report on Tuesday, October 1st. They issued an “outperform” rating and a $84.00 price target on the stock. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $76.74.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.